`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`SHILPA PHARMA, INC.,
`
`Plaintiff,
`
`v.
`
`NOVARTIS PHARMACEUTICALS
`CORPORATION,
`
`Defendant.
`
`C.A. No. 21- 558-MN
`
`JURY TRIAL DEMANDED
`
`NOVARTIS’S RULE 12(C) MOTION TO DISMISS
`SHILPA’S CLAIMS OF WILLFUL INFRINGEMENT
`
`Defendant Novartis Pharmaceuticals Corporation moves pursuant to Federal Rule of Civil
`
`Procedure 12(c) to dismiss Shilpa’s claims of willful and intentional direct and indirect
`
`infringement. Novartis’s proposed order is attached hereto, and the bases for this Motion are set
`
`forth in Novartis’s Opening Brief filed contemporaneously herewith.
`
`MCCARTER & ENGLISH, LLP
`
` /s/ Daniel M. Silver
`Daniel M. Silver (#4758)
`Alexandra M. Joyce (#6423)
`Renaissance Centre
`405 N. King Street, 8th Floor
`Wilmington, Delaware 19801
`(302) 984-6300
`dsilver@mccarter.com
`ajoyce@mccarter.com
`
`Counsel for Defendant Novartis
`Pharmaceuticals Corporation
`
`Dated: May 25, 2022
`
`OF COUNSEL:
`
`Jane M. Love, Ph.D
`Robert W. Trenchard
`GIBSON, DUNN & CRUTCHER LLP
`200 Park Avenue
`New York, NY 10166
`Tel: (212) 351-4000
`jlove@gibsondunn.com
`rtrenchard@gibsondunn.com
`
`ME1 40712895v.1
`
`